Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Voice change

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    27 result(s) found for: Voice change. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2004-004409-24 Sponsor Protocol Number: AK130940 Start Date*: 2005-06-08
    Sponsor Name:GlaxoSmithKline Research & Development
    Full Title: A Multi-Centre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible Dose Study to Evaluate the Efficacy, Safety and Tolerability of Extended-Release Bupropion Hydrochloride (150m...
    Medical condition: Major Depressive Disorder (MDD)
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: SK (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-003803-19 Sponsor Protocol Number: WXL101497 Start Date*: 2004-11-10
    Sponsor Name:GlaxoSmithKline Research & Development
    Full Title: A Multi-Centre, Randomised, Double-Blind, Parallel-Group, Placebo- and Active- Controlled, Flexible Dose Study Evaluating the Efficacy, Safety and Tolerability of Extended-Release Bupropion Hydroch...
    Medical condition: Major Depressive Disorder (MDD)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2014-000184-40 Sponsor Protocol Number: 20130173 Start Date*: 2014-09-11
    Sponsor Name:Amgen, Inc.
    Full Title: Prospective, Multicenter, Single-arm Study to Evaluate Efficacy, Safety, and Pharmacokinetics of Denosumab in Children With Osteogenesis Imperfecta
    Medical condition: Osteogenesis Imperfecta
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10031243 Osteogenesis imperfecta PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) GB (GB - no longer in EU/EEA) HU (Completed) ES (Completed) Outside EU/EEA BG (Completed) PL (Prematurely Ended) BE (Completed) FR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-005959-42 Sponsor Protocol Number: CN138-502 Start Date*: 2008-06-18
    Sponsor Name:Bristol Myers Squibb International Corporation
    Full Title: A 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Efficacy and Safety of Adjunctive Aripiprazole Therapy in the Treatment of Mania in Bipolar I Disorder Pat...
    Medical condition: Bipolar I Mania (manic or mixed episode)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10026749 Mania LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) ES (Completed) CZ (Completed) AT (Completed) HU (Completed) IT (Completed) PL (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2012-003304-12 Sponsor Protocol Number: A0081279 Start Date*: 2013-02-12
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017
    Full Title: A Randomized Double Blind Placebo Controlled Parallel Group Study of the Efficacy and Safety of Pregabalin (BID) in Subjects with Post-Traumatic Peripheral Neuropathic Pain
    Medical condition: Chronic post-traumatic peripheral neuropathic pain
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004852 10054095 Neuropathic pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) DK (Completed) BG (Completed) HU (Completed) BE (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2018-003028-35 Sponsor Protocol Number: CTU/2016/278 Start Date*: 2019-09-04
    Sponsor Name:University College London Comprehensive Clinical Trial Unit
    Full Title: A randomised, double blind, parallel group, placebo controlled, Phase 3 trial of exenatide once weekly over 2 years as a potential disease modifying treatment for Parkinson's disease.
    Medical condition: Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004852 10013113 Disease Parkinson's LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2017-002158-35 Sponsor Protocol Number: IVA_01_ODI_HMPS_17_002 Start Date*: 2017-11-16
    Sponsor Name:Inventiva S.A.
    Full Title: A phase IIa study to investigate safety, Pharmacokinetics, and efficacy of odiparcil in patients 16 years and above with mucopolysaccharidosis (MPS) type VI.
    Medical condition: Mucopolysaccharidosis (MPS) type VI.
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10028095 Mucopolysaccharidosis IV PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) FR (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2020-001696-32 Sponsor Protocol Number: GC2004 Start Date*: 2020-05-08
    Sponsor Name:Instituto Grifols, S.A
    Full Title: A Multicenter, Randomized, Open-label Parallel Group Pilot Study to Evaluate Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) plus Standard Medical Treatment (SMT) versus SMT alo...
    Medical condition: Patients with Mild to Moderate Coronavirus Disease (COVID-19)
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    23.0 10021881 - Infections and infestations 10053983 Corona virus infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2020-001953-36 Sponsor Protocol Number: GC2005 Start Date*: 2020-05-08
    Sponsor Name:Instituto Grifols, S.A
    Full Title: A Multicenter, Randomized, Open-label, Parallel Group Pilot Study to Evaluate the Safety and Efficacy of Prolastin® plus Standard Medical Treatment (SMT) versus SMT alone in Hospitalized Subjects w...
    Medical condition: Patients with Coronavirus Disease (COVID-19)
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    23.0 10021881 - Infections and infestations 10053983 Corona virus infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2014-002941-23 Sponsor Protocol Number: GWEP1423 Start Date*: 2015-09-30
    Sponsor Name:GW Research Ltd.
    Full Title: A randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of cannabidiol (GWP42003-P; CBD) as adjunctive treatment for seizures associated with Lennox- Gastaut syn...
    Medical condition: Lennox-Gastaut syndrome
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029205 - Nervous system disorders 10048816 Lennox-Gastaut syndrome PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2008-001829-33 Sponsor Protocol Number: F1J-US-HMFA Start Date*: 2008-09-15
    Sponsor Name:Eli Lilly and Company
    Full Title: Duloxetine Versus Placebo in the Long-Term Treatment of Patients with Late-Life Major Depression
    Medical condition: Major Depressive Disorder in elderly patients
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012378 Depression LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-011606-41 Sponsor Protocol Number: CP-MGA031-03 Start Date*: 2009-09-15
    Sponsor Name:MacroGenics, Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Multinational, Placebo-Controlled Study to Evaluate Efficacy and Safety of Teplizumab (MGA031), a Humanized, FcR Non-Binding, Anti-CD3 Monoclonal Antibody, in C...
    Medical condition: Recent-onset type 1 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10045228 Type I diabetes mellitus LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: CZ (Completed) NL (Prematurely Ended) ES (Completed) FI (Completed) GB (Completed) DE (Completed) BE (Completed) PL (Completed) FR (Completed) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-005630-36 Sponsor Protocol Number: 2006-57-DPI-2 Start Date*: 2009-05-26
    Sponsor Name:HEXAL AG
    Full Title: Double-blind, double-dummy, multi-center, randomized parallel group study to demonstrate therapeutic equivalence of Salmeterol/Fluticasone DPI HEXAL versus Seretide™ 100 Accuhaler™ over a period of...
    Medical condition: persistent moderate asthma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003555 Asthma bronchial LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: LT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2007-005620-32 Sponsor Protocol Number: 2006-56-DPI-1 Start Date*: 2009-05-08
    Sponsor Name:HEXAL AG
    Full Title: Efficacy and safety of Salmeterol/Fluticasone DPI HEXAL versus Seretide™ Accuhaler™ in adolescent and adult patients with moderate-to-severe persistent asthma: A 12-week, multicenter, randomized, d...
    Medical condition: moderate-to-severe persistent asthma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003555 Asthma bronchial LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: HU (Completed) LT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2007-000135-26 Sponsor Protocol Number: 2006-04-DOS-2 Start Date*: 2007-06-08
    Sponsor Name:Hexal AG
    Full Title: Double-blind, double-dummy, multi-center, randomized parallel group trial to demonstrate therapeutic equivalence of Salmeterol/Fluticasone MDI HEXAL (25 µg/50 µg per actuation) versus SeretideTM 50...
    Medical condition: Persistent, moderate asthma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003555 Asthma bronchial LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: LT (Completed)
    Trial results: View results
    EudraCT Number: 2021-000269-34 Sponsor Protocol Number: GC2010 Start Date*: 2021-03-20
    Sponsor Name:Grifols Therapeutics LLC
    Full Title: A Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of Anti-COVID-19 Immune Globulin (Human) 20% (C19-IG 20%) versus Placebo in Asymptomatic Ambulatory...
    Medical condition: Subjects with laboratory-confirmed novel coronavirus (SARS-CoV-2) infection as determined by qualitative PCR (reverse transcriptase [RT]-PCR) that are asymptomathic
    Disease: Version SOC Term Classification Code Term Level
    23.0 10022891 - Investigations 10084271 SARS-CoV-2 test positive PT
    23.0 100000004862 10084272 SARS-CoV-2 infection LLT
    23.0 100000004862 10084467 Asymptomatic SARS-CoV-2 infection LLT
    23.1 100000004862 10084529 2019 novel coronavirus infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-005235-29 Sponsor Protocol Number: 2007-41-DOS-3 Start Date*: 2008-03-28
    Sponsor Name:HEXAL AG
    Full Title: Efficacy and safety of Salmeterol/Fluticasone MDI HEXAL versus SeretideTM EvohalerTM in adolescent and adult patients with moderate-to-severe persistent asthma: A 12-week, multicenter, randomized, ...
    Medical condition: moderate-to-severe persistent asthma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003555 Asthma bronchial LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2007-000134-39 Sponsor Protocol Number: 2006-03-DOS-1 Start Date*: 2007-04-19
    Sponsor Name:Hexal AG
    Full Title: Double-blind, double-dummy, multi-center, randomized parallel group trial to demonstrate therapeutic equivalence of Salmeterol/Fluticasone MDI HEXAL (25 µg/125 µg per actuation) versus SeretideTM 1...
    Medical condition: persistent moderate asthma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003555 Asthma bronchial LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: LT (Completed) HU (Completed) PL (Ongoing)
    Trial results: View results
    EudraCT Number: 2011-002480-19 Sponsor Protocol Number: A0081275 Start Date*: 2012-01-20
    Sponsor Name:PFIZER, SLU
    Full Title: A PHASE 3B MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED, 2-WAY CROSSOVER STUDY OF PREGABALIN IN THE TREATMENT OF FIBROMYALGIA WITH CONCURRENT ANTIDEPRESSANT THERAPY FOR COMORBID DEPRES...
    Medical condition: This study will be conducted in subjects with fibromyalgia. Subjects will also be on concurrent medication for comorbid depression.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10028395 - Musculoskeletal and connective tissue disorders 10048439 Fibromyalgia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-002457-69 Sponsor Protocol Number: CP-MGA031-01 Start Date*: 2008-12-04
    Sponsor Name:MacroGenics, Inc.
    Full Title: A Phase 2/3, Randomized, Double-Blind, Multicenter, Multinational, 4-Arm, Controlled, Dose-Ranging Study to Evaluate Efficacy and Safety of Teplizumab (MGA031), a Humanized, FcR Non-Binding, Anti-C...
    Medical condition: Recent-onset type I diabetes mellitus (T1DM)
    Disease: Version SOC Term Classification Code Term Level
    9.0 10045228 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) SE (Completed) GB (Completed) EE (Completed) NL (Completed) LV (Completed) ES (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 05 13:21:26 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA